Sold as Lexiscan. Every FDA application for this active ingredient: 1 branded and 13 generic.
As of Nov 13, 2026, FDA lists 14 applications for Regadenoson (sold as Lexiscan), first approved Apr 10, 2008, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Lexiscan | Part B | $8.1M | -47% | 583,372 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Prognostic Value of Oxygen-15 Water PET in Coronary Artery DiseaseCoronary Artery Disease, Microvascular Coronary Artery Disease · Vastra Gotaland Region | Phase 3 | Recruiting | Nov 12, 2026 |
| Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Non Small Cell Lung Cancer, Cardiotoxicity · Indiana University | Phase 2 | Recruiting | Aug 12, 2026 |
| Quantitative Analysis of Cardiac Muscle PerfusionMyocardial Ischemia · St. Anne's University Hospital Brno, Czech Republic | Not applicable | Not yet recruiting | Apr 23, 2026 |
| The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States StudyIschemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging · Brigham and Women's Hospital | Not applicable | Recruiting | Mar 3, 2025 |
| Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic CardiomyopathyCoronary Artery Disease, Coronary Artery Bypass Graft (CABG) · University of Texas Southwestern Medical Center | — | Recruiting | Feb 7, 2025 |
| Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan CirculationUniventricular Heart, Microvascular Dysfunction · Karolinska Institutet | — | Recruiting | Dec 16, 2024 |
| Comparison of the Use of an Outpatient/Mobile MRI Procedure With an Inpatient MRI Procedure in Adult Patients With Known or Suspected Coronary Artery Disease (CAD)Coronary Artery Disease · German Heart Institute | — | Not yet recruiting | Feb 7, 2024 |
| Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PETSickle Cell Disease · St. Jude Children's Research Hospital | Phase 2 | Recruiting | Oct 18, 2022 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 10, 2008 | LexiscanNDA 22161 · New molecular entity | Astellas | 11 | Marketed |
| Apr 11, 2022 | RegadenosonANDA 207604 | Apotex | 0 | Marketed |
| Apr 11, 2022 | RegadenosonANDA 212806 | Meitheal | 0 | Marketed |
| Apr 11, 2022 | RegadenosonANDA 213210 | Dr Reddys | 0 | Marketed |
| Apr 11, 2022 | RegadenosonANDA 213236 | Accord Hlthcare | 2 | Marketed |
| May 23, 2022 | RegadenosonANDA 214252 | Ims Ltd | 0 | Marketed |
| Jul 12, 2022 | RegadenosonANDA 207320 | Gland | 0 | Marketed |
| Aug 31, 2022 | RegadenosonANDA 214349 | Hospira | 0 | Marketed |
| Oct 26, 2022 | RegadenosonANDA 216437 | Eugia Pharma | 0 | Marketed |
| Feb 2, 2023 | RegadenosonANDA 215827 | Hikma | 0 | Marketed |
| Apr 4, 2023 | RegadenosonANDA 213856 | Mylan | 0 | Discontinued |
| May 23, 2023 | RegadenosonANDA 217455 | Baxter Hlthcare Corp | 0 | Marketed |
| Aug 5, 2024 | RegadenosonANDA 215955 | Ge Healthcare | 0 | Discontinued |
| Aug 22, 2024 | RegadenosonANDA 218054 | Indies Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Astellas
Apotex
Ge Healthcare